Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein

Cholangiocarcinoma is a highly lethal cancer with limited therapeutic options. Recent genomic analysis of cholangiocarcinoma has revealed the presence of fibroblast growth factor receptor 2 (FGFR2) fusion proteins in up to 13% of intrahepatic cholangiocarcinoma (iCCA). FGFR fusions have been identif...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Lett
Egile Nagusiak: Wang, Yu, Ding, Xiwei, Wang, Shaoqing, Moser, Catherine D., Shaleh, Hassan M., Mohamed, Essa A., Chaiteerakij, Roongruedee, Allotey, Loretta K., Chen, Gang, Miyabe, Katsuyuki, McNulty, Melissa S., Ndzengue, Albert, Knudson, Ryan A., Greipp, Patricia T., Clark, Karl J., Torbenson, Michael S., Kipp, Benjamin R., Zhou, Jie, Barrett, Michael T., Gustafson, Michael P., Alberts, Steven R., Borad, Mitesh J., Roberts, Lewis R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5119950/
https://ncbi.nlm.nih.gov/pubmed/27216979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2016.05.017
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak